Muscarinic targets for cognition in Schizophrenia; ADHD comorbidity; perinatal risks, treatment resistance and SRIs; and brain lesions presenting as psychiatric illness.
Hollander
Eric
E
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000378:metabolism*; D015897:Comorbidity; D004351:Drug Resistance; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism; D010500:Perinatology; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D011976:Receptors, Muscarinic; D017367:Selective Serotonin Reuptake Inhibitors